drugset
drugset / Trial / NCT05314439

A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension

NCT05314439 ↗

Phase 2 Completed 48 enrolled Ionis Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the effect of ION904 on plasma angiotensinogen (AGT) in participants with uncontrolled hypertension.

Timeline

Start
2022-04-29
Primary completion
2023-01-31
Completion
2023-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Tonlamarsen Unknown — Subcutaneous

Indications

hypertensive disorder